Engineered MSC Line for Osteoinductive Cartilage Grafts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone grafting methods, including autologous transplants and alternative materials, face limitations such as limited availability, increased risks of infection, and safety concerns due to the use of supra-physiological doses of osteoinductive growth factors, highlighting the need for novel strategies that combine the benefits of autologous transplants with the ease of alternative materials without their drawbacks.
Innovation Solution
A mesenchymal stem/stromal cell line capable of chondrogenic differentiation, engineered with transgenes for immortalization and bone morphogenic protein 2 overexpression, is used to generate a decellularized hypertrophic cartilage graft material through 3D perfusion culturing and subsequent devitalization, which is osteoinductive and can be stored easily.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous bone transplant is used, then bone repair quality is improved, but material availability is limited and donor site morbidity increases
Solution Approach 1:
The invention creates an artificial bone graft that copies the essential osteoinductive properties of autologous bone by incorporating BMP-2 protein, which is naturally present in bone tissue. This allows the graft to mimic the biological functionality of patient's own bone without requiring harvesting from the donor site
Solution Approach 2:
The invention uses BMP-2 protein as an intermediary substance that mediates bone formation. The BMP-2 acts as a biological signal that stimulates osteogenesis, serving as a bridge between the synthetic graft material and the patient's natural bone healing process
2Productivity
If supra-physiological doses of osteoinductive growth factors are used, then bone formation is forced, but safety concerns arise due to side effects
Solution Approach 1:
The invention optimizes the concentration of BMP-2 to achieve effective bone formation without using supra-physiological doses. By carefully controlling the amount of BMP-2 incorporated into the graft and the conditions of cell culture, the invention achieves productive bone formation at safe, physiological levels
3Ease of manufacture
If immortalized mesenchymal stem cells with inducible apoptosis are used, then cell-free graft material can be generated, but chondrogenic differentiation fails even in chondrogenic medium
Solution Approach 1:
The invention introduces BMP-2 expression specifically in the context of chondrogenic differentiation. The BMP-2 is produced by the immortalized mesenchymal stem cells during their differentiation into cartilage, creating a localized source of osteoinductive factor within the cartilaginous matrix that subsequently supports bone formation
Data Source
AI summary
A mesenchymal stem/stromal (MSC) cell line, in particular a human mesenchymal stem cell (hMSC), capable of chondrogenic differentiation when cultured in a chondrogenic medium, comprising a first transgene comprising a first nucleic acid sequence encoding for a preferably mammalian immortalizing enzyme under control of a first promoter sequence operable in said mesenchymal cell and a second transgene comprising a second nucleic acid sequence encoding a preferably mammalian bone morphogenic protein under control of a second promoter sequence operable in said mesenchymal cell.